QNTM:NASDAQ, Quantum BioPharma Ltd.
QNTM stock overview
Quantum BioPharma Ltd. (QNTM:NASDAQ) closed at $1.61 on November 13, 2026,
down 9.55% on the day.
The stock trades 87.0% below its 52-week high of $12.42
and 0.6% above its 52-week low of $1.60.
Over the past year, it lost 77.7%.
Quantum BioPharma Ltd. is part of the Health Care sector.
Key figures
- Price
- $1.61
- Day change
- -9.55%
- Volume
- 86,342
- Average volume
- 174,343
- Market cap
- 10M+
- 52-week range
- $1.60 – $12.42
- 50-day average
- $2.92
- 200-day average
- $3.70
Price action over the past year
In 252 trading sessions since November 13, 2025, QNTM closed higher on 97 days (38%).
Its best day was March 24, 2026 (+52.58%) and its worst was March 11, 2026 (-25.00%).
The stock moved 10% or more in a single session 34 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
QNTM news
-
Nov 13, 2026:
Quantum BioPharma achieve 91% increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-Up
-
Nov 11, 2026:
Quantum BioPharma (QNTM) Reports Shareholder Meeting Results, Closes Private Placement Increasing Insider Voting Control
-
Nov 11, 2026:
Quantum BioPharma Announces Results of Annual General and Special Meeting of Shareholders and Closing of Private Placement of Class A Multiple Voting Shares
-
Nov 5, 2026:
Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold
-
Nov 5, 2026:
Quantum BioPharma (QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth
-
Nov 3, 2026:
Quantum BioPharma (QNTM) Draws 'Men's Fitness' Spotlight as Unbuzzd Trial Shows Early Promise
-
Oct 20, 2026:
Quantum BioPharma (QNTM) Featured in Men's Fitness Article Examining Unbuzzd Clinical Trial Results
-
Oct 14, 2026:
Quantum BioPharma's Phase 2 Shows Where Biotech Value Actually Gets Built
About Quantum BioPharma Ltd.
FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative and inflammatory disorders. The three licensed drug candidates are LUCID-MS, a new chemical entity targeting multiple sclerosis, LUCID-PSYCH, a psychoactive molecule targeting major depressive disorder, and FSD-PEA, an ultra-micronized palmitoyl ethylamine with a favorable safety profile targeting inflammation.
Similar stocks
Find more stocks like QNTM with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.